United States Healthcare Equipment & Supplies

AngioDynamics Inc (ANGO)

Track

Track

AngioDynamics Inc. experienced recent insider trading activity involving a significant sale by SVP Warren Nighan. This transaction, totaling approximately $344,006, occurred following the company's July 2026 earnings report. The stock has demonstrated positive momentum, rising 18.8% over the past quarter, currently trading near its 52-week high.
Ticker: ANGO Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for AngioDynamics Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
3.0
Nighan Warren JR SVP Quality and Regulatory Officer
Transaction date
Sale
Price
376.71
Quantity 649 -7.6%
Value US$1,939,314
3.0
WARREN NIGHAN Officer Officer
Transaction date
Proposed sale
Price
90.57
Quantity 16,983
Value US$4,824,474
0.9
Weiss Lawrence T SVP, Chief Legal Officer Officer
Transaction date
Purchase
Price
375.17
Quantity 97,733 -36.5%
Value US$3,806,127
3.2
Trowbridge Stephen A EVP and CFO Officer
Transaction date
Purchase
Price
11.16
Quantity 890 +0.3%
Value US$9,932
3.6
Clemmer James C President and CEO Executive Director
Transaction date
Purchase
Price
11.15
Quantity 10,000 +1.1%
Value US$111,500
3.0
Nighan Warren JR SVP Quality and Regulatory Officer
Transaction date
Sale
Price
12.31
Quantity 4,060 -8.8%
Value US$49,979
3.0
Nighan Warren JR Officer Officer
Transaction date
Proposed sale
Price
12.31
Quantity 4,060
Value US$49,979
3.0
Nighan Warren JR SVP Quality and Regulatory Officer
Transaction date
Purchase
Price
6.08
Quantity 100 +0.2%
Value US$608
3.2
Trowbridge Stephen A EVP and CFO Officer
Transaction date
Purchase
Price
5.86
Quantity 1,700 +1.0%
Value US$9,962
3.0
Nighan Warren JR SVP Quality and Regulatory Officer
Transaction date
Purchase
Price
6.09
Quantity 768 +1.7%
Value US$4,677
3.6
Clemmer James C President and CEO Executive Director
Transaction date
Purchase
Price
6.03
Quantity 20,000 +3.0%
Value US$120,600
3.6
Clemmer James C President and CEO Executive Director
Transaction date
Purchase
Price
6.70
Quantity 10,000 +1.9%
Value US$67,000
3.6
Helsel Dave SVP Global Operations and R&D Officer
Transaction date
Sale
Price
12.95
Quantity 4,633 -19.4%
Value US$59,997
3.2
Trowbridge Stephen A EVP and CFO Officer
Transaction date
Purchase
Price
13.82
Quantity 1,083 +1.2%
Value US$14,967
3.6
Clemmer James C President and CEO Executive Director
Transaction date
Purchase
Price
15.00
Quantity 10,000 +2.3%
Value US$150,000
3.6
Helsel Dave SVP Global Operations and R&D Officer
Transaction date
Sale
Price
22.44
Quantity 5,000 -17.3%
Value US$112,200
3.6
Helsel Dave SVP Global Operations and R&D Officer
Transaction date
Sale
Price
22.44
Quantity 3,513 -13.3%
Value US$78,832
2.3
JOHNSON WESLEY Non-Executive Director
Transaction date
Sale
Price
23.26
Quantity 1,299 -1.6%
Value US$30,215
2.3
JOHNSON WESLEY Non-Executive Director
Transaction date
Sale
Price
23.00
Quantity 6,201 -7.2%
Value US$142,623
3.2
Trowbridge Stephen A EVP and CFO Officer
Transaction date
Purchase
Price
22.64
Quantity 1,000 +1.3%
Value US$22,640
3.6
Clemmer James C President and CEO Executive Director
Transaction date
Purchase
Price
22.84
Quantity 10,000 +2.6%
Value US$228,400
3.6
Helsel Dave SVP Global Operations and R&D Officer
Transaction date
Sale
Price
27.97
Quantity 3,494 -11.7%
Value US$97,727
2.4
Centea Scott Sr. VP/GM, Global VIT Officer
Transaction date
Sale
Price
27.92
Quantity 12,000 -20.6%
Value US$335,040
1.6
Campbell Chad Thomas SVP/GM, Vascular Access Officer
Transaction date
Sale
Price
27.15
Quantity 10,748 -25.3%
Value US$291,808
3.6
Helsel Dave SVP Global Operations and R&D Officer
Transaction date
Sale
Price
23.93
Quantity 3,500 -15.5%
Value US$83,755
2.3
JOHNSON WESLEY Non-Executive Director
Transaction date
Sale
Price
18.53
Quantity 6,500 -7.7%
Value US$120,445
3.2
Trowbridge Stephen A EVP and CFO Officer
Transaction date
Purchase
Price
9.38
Quantity 1,013 +1.7%
Value US$9,502
3.6
Clemmer James C President and CEO Executive Director
Transaction date
Purchase
Price
8.26
Quantity 40,000 +13.2%
Value US$330,400
3.6
Clemmer James C President and CEO Executive Director
Transaction date
Purchase
Price
14.19
Quantity 15,000 +6.1%
Value US$212,850
3.2
Gould Kevin J
Transaction date
Sale
Price
21.45
Quantity 13,650 -19.8%
Value US$292,792
Greiner Michael EVP and CFO Officer
Transaction date
Sale
Price
21.53
Quantity 1,939 -8.6%
Value US$41,747
Richard Stark SVP, GM - Oncology
Transaction date
Sale
Price
16.29
Quantity 27,409 -56.9%
Value US$446,493
REED JAN STERN Non-Executive Director
Transaction date
Purchase
Price
16.00
Quantity 316 +inf%
Value US$5,056
Clemmer James C President and CEO Executive Director
Transaction date
Purchase
Price
15.79
Quantity 5,000 +5.8%
Value US$78,950
DONNELLY HOWARD W Non-Executive Director
Transaction date
Purchase
Price
15.72
Quantity 5,000 +11.7%
Value US$78,600
Clemmer James C President and CEO Executive Director
Transaction date
Purchase
Price
15.64
Quantity 20,000 +30.0%
Value US$312,800
Avista Capital Partners GP, LLC Large shareholder
Transaction date
Sale
Price
16.00
Quantity 384,184 -50.2%
Value US$6,146,944
Avista Capital Partners GP, LLC Large shareholder
Transaction date
Sale
Price
16.00
Quantity 508,869 -50.2%
Value US$8,141,904
Avista Capital Partners GP, LLC Large shareholder
Transaction date
Sale
Price
16.00
Quantity 1,456,947 -50.2%
Value US$23,311,152
Burgstahler David F Large shareholder
Transaction date
Sale
Price
16.00
Quantity 384,184 -50.2%
Value US$6,146,944
Burgstahler David F Large shareholder
Transaction date
Sale
Price
16.00
Quantity 508,869 -50.2%
Value US$8,141,904
Burgstahler David F Large shareholder
Transaction date
Sale
Price
16.00
Quantity 1,456,947 -50.2%
Value US$23,311,152
Avista Capital Partners GP, LLC Large shareholder
Transaction date
Sale
Price
15.68
Quantity 541,349 -34.8%
Value US$8,488,352
Burgstahler David F Non-Executive Director Large shareholder
Transaction date
Sale
Price
15.68
Quantity 541,349 -34.8%
Value US$8,488,352
Avista Capital Partners GP, LLC Large shareholder
Transaction date
Sale
Price
15.68
Quantity 1,549,945 -34.8%
Value US$24,303,138
Burgstahler David F Non-Executive Director Large shareholder
Transaction date
Sale
Price
15.68
Quantity 1,549,945 -34.8%
Value US$24,303,138
Burgstahler David F Non-Executive Director Large shareholder
Transaction date
Sale
Price
14.62
Quantity 487,214 -23.9%
Value US$7,123,069
Burgstahler David F Non-Executive Director Large shareholder
Transaction date
Sale
Price
14.62
Quantity 367,836 -23.9%
Value US$5,377,762
Avista Capital Partners GP, LLC Large shareholder
Transaction date
Sale
Price
14.62
Quantity 478,214 -23.5%
Value US$6,991,489
Avista Capital Partners GP, LLC Large shareholder
Transaction date
Sale
Price
14.62
Quantity 367,836 -23.9%
Value US$5,377,762
Burgstahler David F Non-Executive Director Large shareholder
Transaction date
Sale
Price
14.62
Quantity 1,394,950 -23.9%
Value US$20,394,169
Avista Capital Partners GP, LLC Large shareholder
Transaction date
Sale
Price
14.62
Quantity 1,394,950 -23.9%
Value US$20,394,169
Greiner Charles R VP - Global Franchise Officer
Transaction date
Sale
Price
12.31
Quantity 3,508 -14.4%
Value US$43,183
Trowbridge Stephen A SVP and General Counsel Officer
Transaction date
Sale
Price
12.18
Quantity 2,440 -7.5%
Value US$29,719
Trowbridge Stephen A SVP and General Counsel Officer
Transaction date
Sale
Price
12.33
Quantity 10,500 -24.4%
Value US$129,465
Richard Stark SVP, GM - Oncology Officer
Transaction date
Sale
Price
18.53
Quantity 18,100 -38.7%
Value US$335,393
Greiner Charles R VP - Global Franchise Officer
Transaction date
Sale
Price
15.63
Quantity 3,298 -13.0%
Value US$51,548
Greiner Charles R VP - Global Finance Officer
Transaction date
Sale
Price
15.46
Quantity 4,373 -15.9%
Value US$67,611
Greiner Charles R VP - Global Finance Officer
Transaction date
Sale
Price
15.40
Quantity 2,392 -9.4%
Value US$36,842
BUCCI VINCENT Non-Executive Director
Transaction date
Purchase
Price
15.20
Quantity 5,000 +6.1%
Value US$75,990
DONNELLY HOWARD W Non-Executive Director
Transaction date
Sale
Price
15.06
Quantity 20,000 -55.8%
Value US$301,200
Gould Kevin J Non-Executive Director
Transaction date
Purchase
Price
12.00
Quantity 2,700 +32.7%
Value US$32,400
BUCCI VINCENT Non-Executive Director
Transaction date
Purchase
Price
10.80
Quantity 10,000 +333.3%
Value US$108,000
BUCCI VINCENT Non-Executive Director
Transaction date
Purchase
Price
10.76
Quantity 35,000 +1166.7%
Value US$376,600
BUCCI VINCENT Non-Executive Director
Transaction date
Purchase
Price
10.78
Quantity 40,000 +103.4%
Value US$431,200
Meteny Dennis S Non-Executive Director
Transaction date
Purchase
Price
10.82
Quantity 4,600 +26.5%
Value US$49,772
BUCCI VINCENT Non-Executive Director
Transaction date
Purchase
Price
12.17
Quantity 2,000 +5.5%
Value US$24,332
Gould Kevin J Non-Executive Director
Transaction date
Purchase
Price
11.58
Quantity 2,700 +48.6%
Value US$31,277
GOLD JEFFREY Non-Executive Director
Transaction date
Purchase
Price
10.56
Quantity 1,000 +4.1%
Value US$10,560
Richard Stark SVP, GM - Oncology Officer
Transaction date
Sale
Price
10.36
Quantity 3,160 -10.9%
Value US$32,738
DEVIVO JOSEPH President and CEO Executive Director
Transaction date
Purchase
Price
11.67
Quantity 2,000 +5.6%
Value US$23,340
Richard Stark SVP, GM - Oncology Officer
Transaction date
Sale
Price
12.42
Quantity 2,080 -9.0%
Value US$25,827
BUCCI VINCENT Non-Executive Director
Transaction date
Purchase
Price
11.82
Quantity 4,000 +inf%
Value US$47,280
Gould Kevin J Non-Executive Director
Transaction date
Purchase
Price
11.72
Quantity 2,700 +inf%
Value US$31,636
Kapusta Matthew C SVP, Business Development Officer
Transaction date
Purchase
Price
11.40
Quantity 1,000 +6.7%
Value US$11,397
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-07-31 2026-07-30 S Sale
3.0
Nighan Warren JR

SVP Quality and Regulatory

Officer
649 -7.6%
376.71
US$1,939,314 		649 -7.6% 376.71 US$1,939,314
2026-07-30 2026-07-30 PrS Proposed sale
3.0
WARREN NIGHAN

Officer

Officer
16,983
90.57
US$4,824,474 		16,983 90.57 US$4,824,474
2025-10-22 2025-10-21 B Purchase
0.9
Weiss Lawrence T

SVP, Chief Legal Officer

Officer
97,733 -36.5%
375.17
US$3,806,127 		97,733 -36.5% 375.17 US$3,806,127
2025-10-14 2025-10-13 B Purchase
3.2
Trowbridge Stephen A

EVP and CFO

Officer
890 +0.3%
11.16
US$9,932 		890 +0.3% 11.16 US$9,932
2025-10-09 2025-10-09 B Purchase
3.6
Clemmer James C

President and CEO

Executive Director
10,000 +1.1%
11.15
US$111,500 		10,000 +1.1% 11.15 US$111,500
2025-01-17 2025-01-16 S Sale
3.0
Nighan Warren JR

SVP Quality and Regulatory

Officer
4,060 -8.8%
12.31
US$49,979 		4,060 -8.8% 12.31 US$49,979
2025-01-16 2025-01-16 PrS Proposed sale
3.0
Nighan Warren JR

Officer

Officer
4,060
12.31
US$49,979 		4,060 12.31 US$49,979
2024-10-10 2024-10-10 B Purchase
3.0
Nighan Warren JR

SVP Quality and Regulatory

Officer
100 +0.2%
6.08
US$608 		100 +0.2% 6.08 US$608
2024-10-08 2024-10-08 B Purchase
3.2
Trowbridge Stephen A

EVP and CFO

Officer
1,700 +1.0%
5.86
US$9,962 		1,700 +1.0% 5.86 US$9,962
2024-10-10 2024-10-07 B Purchase
3.0
Nighan Warren JR

SVP Quality and Regulatory

Officer
768 +1.7%
6.09
US$4,677 		768 +1.7% 6.09 US$4,677
2024-10-08 2024-10-07 B Purchase
3.6
Clemmer James C

President and CEO

Executive Director
20,000 +3.0%
6.03
US$120,600 		20,000 +3.0% 6.03 US$120,600
2024-04-08 2024-04-08 B Purchase
3.6
Clemmer James C

President and CEO

Executive Director
10,000 +1.9%
6.70
US$67,000 		10,000 +1.9% 6.70 US$67,000
2023-02-01 2023-01-31 S Sale
3.6
Helsel Dave

SVP Global Operations and R&D

Officer
4,633 -19.4%
12.95
US$59,997 		4,633 -19.4% 12.95 US$59,997
2022-10-12 2022-10-12 B Purchase
3.2
Trowbridge Stephen A

EVP and CFO

Officer
1,083 +1.2%
13.82
US$14,967 		1,083 +1.2% 13.82 US$14,967
2022-10-11 2022-10-10 B Purchase
3.6
Clemmer James C

President and CEO

Executive Director
10,000 +2.3%
15.00
US$150,000 		10,000 +2.3% 15.00 US$150,000
2022-08-01 2022-07-29 S Sale
3.6
Helsel Dave

SVP Global Operations and R&D

Officer
5,000 -17.3%
22.44
US$112,200 		5,000 -17.3% 22.44 US$112,200
2022-05-02 2022-04-28 S Sale
3.6
Helsel Dave

SVP Global Operations and R&D

Officer
3,513 -13.3%
22.44
US$78,832 		3,513 -13.3% 22.44 US$78,832
2022-04-13 2022-04-12 S Sale
2.3
JOHNSON WESLEY
Non-Executive Director
1,299 -1.6%
23.26
US$30,215 		1,299 -1.6% 23.26 US$30,215
2022-04-13 2022-04-11 S Sale
2.3
JOHNSON WESLEY
Non-Executive Director
6,201 -7.2%
23.00
US$142,623 		6,201 -7.2% 23.00 US$142,623
2022-01-12 2022-01-12 B Purchase
3.2
Trowbridge Stephen A

EVP and CFO

Officer
1,000 +1.3%
22.64
US$22,640 		1,000 +1.3% 22.64 US$22,640
2022-01-12 2022-01-11 B Purchase
3.6
Clemmer James C

President and CEO

Executive Director
10,000 +2.6%
22.84
US$228,400 		10,000 +2.6% 22.84 US$228,400
2021-10-21 2021-10-20 S Sale
3.6
Helsel Dave

SVP Global Operations and R&D

Officer
3,494 -11.7%
27.97
US$97,727 		3,494 -11.7% 27.97 US$97,727
2021-10-18 2021-10-15 S Sale
2.4
Centea Scott

Sr. VP/GM, Global VIT

Officer
12,000 -20.6%
27.92
US$335,040 		12,000 -20.6% 27.92 US$335,040
2021-10-06 2021-10-05 S Sale
1.6
Campbell Chad Thomas

SVP/GM, Vascular Access

Officer
10,748 -25.3%
27.15
US$291,808 		10,748 -25.3% 27.15 US$291,808
2021-04-15 2021-04-14 S Sale
3.6
Helsel Dave

SVP Global Operations and R&D

Officer
3,500 -15.5%
23.93
US$83,755 		3,500 -15.5% 23.93 US$83,755
2021-01-21 2021-01-20 S Sale
2.3
JOHNSON WESLEY
Non-Executive Director
6,500 -7.7%
18.53
US$120,445 		6,500 -7.7% 18.53 US$120,445
2020-08-12 2020-08-11 B Purchase
3.2
Trowbridge Stephen A

EVP and CFO

Officer
1,013 +1.7%
9.38
US$9,502 		1,013 +1.7% 9.38 US$9,502
2020-08-03 2020-07-31 B Purchase
3.6
Clemmer James C

President and CEO

Executive Director
40,000 +13.2%
8.26
US$330,400 		40,000 +13.2% 8.26 US$330,400
2019-10-28 2019-10-25 B Purchase
3.6
Clemmer James C

President and CEO

Executive Director
15,000 +6.1%
14.19
US$212,850 		15,000 +6.1% 14.19 US$212,850
2019-07-18 2019-07-16 S Sale
3.2
Gould Kevin J
13,650 -19.8%
21.45
US$292,792 		13,650 -19.8% 21.45 US$292,792
2018-11-08 2018-11-07 S Sale Greiner Michael

EVP and CFO

Officer
1,939 -8.6%
21.53
US$41,747 		1,939 -8.6% 21.53 US$41,747
2017-11-17 2017-11-15 S Sale Richard Stark

SVP, GM - Oncology
27,409 -56.9%
16.29
US$446,493 		27,409 -56.9% 16.29 US$446,493
2017-07-25 2017-07-24 B Purchase REED JAN STERN Non-Executive Director
316 +inf%
16.00
US$5,056 		316 +inf% 16.00 US$5,056
2017-07-21 2017-07-21 B Purchase Clemmer James C

President and CEO

Executive Director
5,000 +5.8%
15.79
US$78,950 		5,000 +5.8% 15.79 US$78,950
2017-07-21 2017-07-21 B Purchase DONNELLY HOWARD W Non-Executive Director
5,000 +11.7%
15.72
US$78,600 		5,000 +11.7% 15.72 US$78,600
2017-07-21 2017-07-20 B Purchase Clemmer James C

President and CEO

Executive Director
20,000 +30.0%
15.64
US$312,800 		20,000 +30.0% 15.64 US$312,800
2017-04-14 2017-04-12 S Sale Avista Capital Partners GP, LLC Large shareholder
384,184 -50.2%
16.00
US$6,146,944 		384,184 -50.2% 16.00 US$6,146,944
2017-04-14 2017-04-12 S Sale Avista Capital Partners GP, LLC Large shareholder
508,869 -50.2%
16.00
US$8,141,904 		508,869 -50.2% 16.00 US$8,141,904
2017-04-14 2017-04-12 S Sale Avista Capital Partners GP, LLC Large shareholder
1,456,947 -50.2%
16.00
US$23,311,152 		1,456,947 -50.2% 16.00 US$23,311,152
2017-04-14 2017-04-12 S Sale Burgstahler David F Large shareholder
384,184 -50.2%
16.00
US$6,146,944 		384,184 -50.2% 16.00 US$6,146,944
2017-04-14 2017-04-12 S Sale Burgstahler David F Large shareholder
508,869 -50.2%
16.00
US$8,141,904 		508,869 -50.2% 16.00 US$8,141,904
2017-04-14 2017-04-12 S Sale Burgstahler David F Large shareholder
1,456,947 -50.2%
16.00
US$23,311,152 		1,456,947 -50.2% 16.00 US$23,311,152
2016-11-22 2016-11-18 S Sale Avista Capital Partners GP, LLC Large shareholder
541,349 -34.8%
15.68
US$8,488,352 		541,349 -34.8% 15.68 US$8,488,352
2016-11-22 2016-11-18 S Sale Burgstahler David F Non-Executive Director Large shareholder
541,349 -34.8%
15.68
US$8,488,352 		541,349 -34.8% 15.68 US$8,488,352
2016-11-22 2016-11-18 S Sale Avista Capital Partners GP, LLC Large shareholder
1,549,945 -34.8%
15.68
US$24,303,138 		1,549,945 -34.8% 15.68 US$24,303,138
2016-11-22 2016-11-18 S Sale Burgstahler David F Non-Executive Director Large shareholder
1,549,945 -34.8%
15.68
US$24,303,138 		1,549,945 -34.8% 15.68 US$24,303,138
2016-08-05 2016-08-05 S Sale Burgstahler David F Non-Executive Director Large shareholder
487,214 -23.9%
14.62
US$7,123,069 		487,214 -23.9% 14.62 US$7,123,069
2016-08-05 2016-08-05 S Sale Burgstahler David F Non-Executive Director Large shareholder
367,836 -23.9%
14.62
US$5,377,762 		367,836 -23.9% 14.62 US$5,377,762
2016-08-05 2016-08-05 S Sale Avista Capital Partners GP, LLC Large shareholder
478,214 -23.5%
14.62
US$6,991,489 		478,214 -23.5% 14.62 US$6,991,489
2016-08-05 2016-08-05 S Sale Avista Capital Partners GP, LLC Large shareholder
367,836 -23.9%
14.62
US$5,377,762 		367,836 -23.9% 14.62 US$5,377,762
2016-08-05 2016-08-05 S Sale Burgstahler David F Non-Executive Director Large shareholder
1,394,950 -23.9%
14.62
US$20,394,169 		1,394,950 -23.9% 14.62 US$20,394,169
2016-08-05 2016-08-05 S Sale Avista Capital Partners GP, LLC Large shareholder
1,394,950 -23.9%
14.62
US$20,394,169 		1,394,950 -23.9% 14.62 US$20,394,169
2016-05-09 2016-05-06 S Sale Greiner Charles R

VP - Global Franchise

Officer
3,508 -14.4%
12.31
US$43,183 		3,508 -14.4% 12.31 US$43,183
2016-04-25 2016-04-25 S Sale Trowbridge Stephen A

SVP and General Counsel

Officer
2,440 -7.5%
12.18
US$29,719 		2,440 -7.5% 12.18 US$29,719
2016-04-25 2016-04-21 S Sale Trowbridge Stephen A

SVP and General Counsel

Officer
10,500 -24.4%
12.33
US$129,465 		10,500 -24.4% 12.33 US$129,465
2015-02-19 2015-02-13 S Sale Richard Stark

SVP, GM - Oncology

Officer
18,100 -38.7%
18.53
US$335,393 		18,100 -38.7% 18.53 US$335,393
2014-10-21 2014-10-20 S Sale Greiner Charles R

VP - Global Franchise

Officer
3,298 -13.0%
15.63
US$51,548 		3,298 -13.0% 15.63 US$51,548
2013-11-15 2013-11-14 S Sale Greiner Charles R

VP - Global Finance

Officer
4,373 -15.9%
15.46
US$67,611 		4,373 -15.9% 15.46 US$67,611
2013-11-15 2013-11-13 S Sale Greiner Charles R

VP - Global Finance

Officer
2,392 -9.4%
15.40
US$36,842 		2,392 -9.4% 15.40 US$36,842
2013-10-21 2013-10-18 B Purchase BUCCI VINCENT Non-Executive Director
5,000 +6.1%
15.20
US$75,990 		5,000 +6.1% 15.20 US$75,990
2013-10-21 2013-10-17 S Sale DONNELLY HOWARD W Non-Executive Director
20,000 -55.8%
15.06
US$301,200 		20,000 -55.8% 15.06 US$301,200
2013-07-23 2013-07-22 B Purchase Gould Kevin J Non-Executive Director
2,700 +32.7%
12.00
US$32,400 		2,700 +32.7% 12.00 US$32,400
2013-03-13 2013-03-12 B Purchase BUCCI VINCENT Non-Executive Director
10,000 +333.3%
10.80
US$108,000 		10,000 +333.3% 10.80 US$108,000
2013-03-13 2013-03-12 B Purchase BUCCI VINCENT Non-Executive Director
35,000 +1166.7%
10.76
US$376,600 		35,000 +1166.7% 10.76 US$376,600
2013-03-13 2013-03-12 B Purchase BUCCI VINCENT Non-Executive Director
40,000 +103.4%
10.78
US$431,200 		40,000 +103.4% 10.78 US$431,200
2013-03-12 2013-03-12 B Purchase Meteny Dennis S Non-Executive Director
4,600 +26.5%
10.82
US$49,772 		4,600 +26.5% 10.82 US$49,772
2013-02-15 2013-02-14 B Purchase BUCCI VINCENT Non-Executive Director
2,000 +5.5%
12.17
US$24,332 		2,000 +5.5% 12.17 US$24,332
2013-01-14 2013-01-11 B Purchase Gould Kevin J Non-Executive Director
2,700 +48.6%
11.58
US$31,277 		2,700 +48.6% 11.58 US$31,277
2012-11-13 2012-11-05 B Purchase GOLD JEFFREY Non-Executive Director
1,000 +4.1%
10.56
US$10,560 		1,000 +4.1% 10.56 US$10,560
2012-11-09 2012-11-05 S Sale Richard Stark

SVP, GM - Oncology

Officer
3,160 -10.9%
10.36
US$32,738 		3,160 -10.9% 10.36 US$32,738
2012-07-18 2012-07-17 B Purchase DEVIVO JOSEPH

President and CEO

Executive Director
2,000 +5.6%
11.67
US$23,340 		2,000 +5.6% 11.67 US$23,340
2012-05-17 2012-05-16 S Sale Richard Stark

SVP, GM - Oncology

Officer
2,080 -9.0%
12.42
US$25,827 		2,080 -9.0% 12.42 US$25,827
2012-04-13 2012-04-12 B Purchase BUCCI VINCENT Non-Executive Director
4,000 +inf%
11.82
US$47,280 		4,000 +inf% 11.82 US$47,280
2012-04-12 2012-04-11 B Purchase Gould Kevin J Non-Executive Director
2,700 +inf%
11.72
US$31,636 		2,700 +inf% 11.72 US$31,636
2012-04-10 2012-04-10 B Purchase Kapusta Matthew C

SVP, Business Development

Officer
1,000 +6.7%
11.40
US$11,397 		1,000 +6.7% 11.40 US$11,397
Explore more

More insider trading research around AngioDynamics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Healthcare Services companies with insider activity
More Healthcare Equipment & Supplies companies with insider activity
Insider trading in North America